Merck Group - Search News

Weak 2025 Guidance Mangles Merck Stock Today

Merck beats estimates on fourth-quarter on earnings—but stock slides pre-market on tepid 2025 guidance

Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 8% in pre-market trading, largely because of weaker than expected 2025 guidance.

Business Insider · 1d

MRK Earnings: Weak 2025 Guidance Mangles Merck Stock Today

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted

MarketWatch on MSN · 1d

Merck’s soft guidance overshadows quarterly beat to send stock down 6%

Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset better-than-expected fourth-quarter earnings.

Merck 2025 Sales Forecast Underwhelms

U.S. News & World Report · 1d

Merck 2025 Sales Forecast Underwhelms as It Pauses Gardasil Sales in China

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling produ

The Financial Times · 1d

Merck shares sink 11% after vaccine shipments to China halted

Merck blamed the lower than expected forecast on the decision to pause shipments of its Gardasil vaccine to China until at least mid-year. Gardasil is given to patients to prevent human papillomavirus, which is linked with cervical cancer.

Bloomberg on MSN · 1d

Merck’s Gardasil Halt Shows Blockbuster Shots’ Dilemma in China

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US pharmaceutical giant made the call earlier this week to halt shipments.

Investor's Business Daily on MSN1d

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares

Investors hammered Merck stock Tuesday after the company beat fourth-quarter expectations, but delivered a light 2025 outlook.

20hon MSN

Dow's 140-point fall led by losses for shares of UnitedHealth, Merck

The Dow Jones Industrial Average is down Wednesday morning with shares of UnitedHealth and Merck seeing the biggest drops for the price-weighted average.

pharmaphorum7d

Merck puts big bucks behind ADC alliance with China's Kelun

according to Chinese media group Yicai Global, with the second for an as-yet-unidentified ADC having a value of around %950 million. For some time, industry observers have been asking what Merck ...

Seeking Alpha6d

MRK Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

16d

Why WEC Energy, Fifth Third Bancorp And Merck Are Winners For Passive Income

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. WEC Energy, Fifth Third Bancorp and Merck have rewarded shareholders for ...

pharmaphorum4d

Merck’s cardiovascular pipeline delivers at ACC

Just 2% of patients on MK-0616 discontinued treatment due to adverse events, compared to 1% of the placebo group. A key advantage for Merck’s drug is that it could slot into therapy alongside ...

appliedclinicaltrialsonline6d

Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the ...

Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results